This suggests that quantitative indicators based on the expression level of CYP7A1 and primary bile acid levels may serve as effective biomarkers for predicting HCC and diagnosing NASH at an early stage. This evidence concerns the gene CYP7A1 and metabolic dysfunction-associated steatohepatitis.